A recent breakthrough using the immune checkpoint inhibitors (ICIs) targeting programmed cell death ligand 1 (PDL1) and vascular endothelial factor (VEGF)A indicates the longer overall survival of unresectable cases in comparison to the use of sorafenib in advanced HCC patients [90]. The gene discussed is CD274; the disease is hepatocellular carcinoma.